BioSpace News Archive

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, provided a business update and reported financial results for the third quarter of 2021.

TG Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the remainder of 2021.

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced positive topline results from its OCS donors after circulatory death Heart Trial.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced financial results for the third quarter ended September 30, 2021, and reviewed recent corporate updates and program highlights.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that management will host a conference call and live audio webcast on November 10, 2021 at 8:30 a.m. ET to discuss third quarter 2021 results and provide a general business update.

Concert Pharmaceuticals, Inc. announced that it has entered into an agreement with BVF Partners L.P. and RA Capital Management to raise gross proceeds of $65 million.

Personalis, Inc., a leader in advanced genomics for cancer and population sequencing, reported financial results for the third quarter ended September 30, 2021.

bluebird bio, Inc . (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company.

PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, announced that it has raised $75.5 million in Series B financing.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on November 3, 2021 as inducements material to each employee entering into employment with KalVista.